Resultats globals: 2 registres trobats en 0.02 segons.
Articles, 2 registres trobats
Articles 2 registres trobats  
1.
16 p, 1.2 MB Deucravacitinib in Moderate to Severe Psoriasis : Clinical and Quality-of-Life Outcomes in a Phase 2 Trial / Thaçi, Diamant (University of Luebeck) ; Strober, Bruce (Yale University) ; Gordon, Kenneth B. (Medical College of Wisconsin) ; Foley, Peter (The University of Melbourne) ; Gooderham, Melinda (Queen's University and Probity Medical Research) ; Morita, Akimichi (Nagoya City University) ; Papp, Kim A. (Clinical Research and Probity Medical Research) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Menter, M. Alan (Baylor University Medical Center) ; Colombo, Matthew J. (Bristol Myers Squibb) ; Elbez, Yedid (Bristol Myers Squibb) ; Kisa, Renata M. (Bristol Myers Squibb) ; Ye, June (Bristol Myers Squibb) ; Napoli, Andrew A. (Bristol Myers Squibb) ; Wei, Lan (Bristol Myers Squibb) ; Banerjee, Subhashis (Bristol Myers Squibb) ; Merola, Joseph F. (Harvard Medical School) ; Gottlieb, Alice B. (Icahn School of Medicine at Mount Sinai) ; Universitat Autònoma de Barcelona
Deucravacitinib is an oral, selective tyrosine kinase 2 inhibitor that demonstrated therapeutic benefit in a Phase 2 clinical trial of adults with moderate to severe plaque psoriasis. This analysis was designed to evaluate the effect of deucravacitinib on additional clinical and quality-of-life (QoL) outcomes and assess the relationship between these outcomes in adults with psoriasis. [...]
2022 - 10.1007/s13555-021-00649-y
Dermatology and Therapy, Vol. 12 (january 2022) , p. 495-510  
2.
18 p, 504.6 KB Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis : Results from Greater Than 17,000 Patient-Years of Exposure / Armstrong, April (Keck School of Medicine of the University of Southern California. Department of Clinical Research) ; Paul, Carle (Paul Sabatier University. Dermatology Department, Toulouse University Hospital (CHU)) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Boehncke, Wolf Henning (University of Geneva. Department of Pathology and Immunology) ; Freeman, Michael (The Skin Centre, Benowa, QLD Australia) ; Torii, Hideshi (Tokyo Yamate Medical Center. Division of Dermatology) ; Papp, Kim (K Papp Clinical Research and Probity Medical Research) ; Griffiths, Christopher E. M. (NIHR Manchester Biomedical Research Centre. Dermatology Centre, Salford Royal Hospital, University of Manchester) ; Blauvelt, Andrew (Oregon Medical Research Center) ; Reich, Kristian (Skinflammation® Center, Hamburg, Germany) ; Gooderham, Melinda (Centre for Dermatology and Probity Medical Research, Peterborough, ON Canada) ; Terui, Tadashi (Nihon University School of Medicine. Department of Dermatology) ; Renda, Lisa (Eli Lilly and Company) ; Agada, Noah (Eli Lilly and Company) ; Xu, Wen (Eli Lilly and Company) ; Gallo, Gaia (Eli Lilly and Company) ; Lebwohl, Mark G. (Icahn School of Medicine at Mount Sinai. Department of Dermatology) ; Universitat Autònoma de Barcelona
Long-term safety data are critical for evaluating therapies for psoriasis. Ixekizumab has demonstrated efficacy and is well tolerated for the treatment of moderate-to-severe plaque psoriasis. We examined the safety and tolerability of up to 5 years of ixekizumab therapy in patients with psoriasis. [...]
2019 - 10.1007/s13555-019-00340-3
Dermatology and Therapy, Vol. 10 (november 2019) , p. 133-150  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.